Meeting
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
Authors
Erika Paige Hamilton
Sarah Cannon Research Institute, Brentwood, TN
Erika Paige Hamilton , Denise A. Yardley , Gabriel N. Hortobagyi , Luke N. Walker , Virginia F. Borges , Stacy L. Moulder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02025192
Citation
J Clin Oncol 33, 2015 (suppl; abstr 602)
DOI
10.1200/jco.2015.33.15_suppl.602
Abstract #
602
Poster Bd #
91
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2015 ASCO Annual Meeting
ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets).
First Author: Cristiano Ferrario
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos